Patents Represented by Attorney Gregory C. Houghton
-
Patent number: 7947673Abstract: The invention relates to combination comprising a pharmaceutically acceptable preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a gallium and its use in diagnosis. The invention also pertains to the use of a compound of formula I or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of an excess iron overload in the human or animal body whereby said body is undergoing gallium scintigraphy and whereby the treatment removing said excess of iron is interrupted for a period of 2 to 10 days prior to the gallium scintigraphy and resumed after the gallium scintigraphy readings.Type: GrantFiled: October 30, 2006Date of Patent: May 24, 2011Assignee: Novartis AGInventors: Hanspeter Nick, Rene Lattmann
-
Patent number: 7939625Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.Type: GrantFiled: November 5, 2008Date of Patent: May 10, 2011Assignee: Novartis AGInventors: Rainer Albert, Wilfried Bauer, David Bodmer, Christian Bruns, Ivo Felner, Heribert Hellstern, Ian Lewis, Mark Meisenbach, Gisbert Weckbecker, Bernhard Wietfeld
-
Patent number: 7615609Abstract: Provided is a process for preparing cyclic somatostatin analogues and the linear intermediates used in this process.Type: GrantFiled: August 6, 2004Date of Patent: November 10, 2009Assignee: Novartis AGInventors: Heribert Hellstern, Werner Pachinger, Walter Prikoszovich, Bernhard Wietfeld
-
Patent number: 7473761Abstract: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.Type: GrantFiled: July 30, 2001Date of Patent: January 6, 2009Assignee: Novartis AGInventors: Rainer Albert, Wilfried Bauer, David Bodmer, Christian Bruns, Ivo Felner, Heribert Hellstern, Ian Lewis, Mark Meisenbach, Gisbert Weckbecker, Bernhard Wietfeld
-
Patent number: 7449587Abstract: The present invention relates to processes for preparing peptides and to intermediates involved in such processes, e.g. a process for preparing a compound of formula VIII wherein R12 and R13 are as defined herein.Type: GrantFiled: August 16, 2007Date of Patent: November 11, 2008Assignee: Novartis AGInventors: Bernhard Wietfeld, Walter Prikoszovich, Bernhard Erb, Werner Pachinger
-
Patent number: 7402603Abstract: The invention relates to a combination which comprises (a) a cyclooxygenase-2 inhibitor (“COX-2 inhibitor”) and (b) a histone deacetylase inhibitor (“HDAI”) for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of pre-malignant colon lesions or a colon cancer or other malignancies in a mammal, particularly a human. The invention also relates to pharmaceutical compositions comprising such a combination and to a method of treating pre-malignant colon lesions (e.g. polyps) and colon cancer, as well as other malignancies, in a mammal, particularly a human, with such a combination. The present invention further also relates to a commercial package or product comprising such a combination.Type: GrantFiled: November 5, 2002Date of Patent: July 22, 2008Assignee: Novartis AGInventors: Ying-Nan Pan Chen, Peter Lassota, Alexander Wallace Wood
-
Patent number: 7273875Abstract: The invention relates to compounds of formula I in free or salt form, where R1 is a monovalent aromatic group having up to 10 carbon atoms, and R2 is a cycloaliphatic group having up to 8 ring carbon atoms. Compositions containing them, methods for their preparation and their use as pharmaceuticals are also described.Type: GrantFiled: November 4, 2002Date of Patent: September 25, 2007Assignee: Novartis AGInventors: Alastair Denholm, Thomas H Keller, Clive McCarthy, Neil J Press, Roger J Taylor
-
Patent number: 7259170Abstract: A pharmaceutical compound comprising a compound of formula I and a pharmaceutically acceptable 2-amino-1,3-propanediol beside one or more pharmaceutically acceptable excipient(s).Type: GrantFiled: October 22, 2002Date of Patent: August 21, 2007Assignee: Novartis AGInventor: Josef G Meingassner
-
Patent number: 7259173Abstract: This invention relates to organic compounds of formula I, in which Ar1 is unsubstituted phenyl substituted by one or more halogen atoms; Ar2 is unsubstituted phenyl or phenyl substituted by one or more substituents selected from the group consisting of halogen, cyano and C1-C8-alkoxy; R1 is hydrogen or methyl optionally substituted by hydroxy; R10 is hydrogen or hydroxy; and pharmaceutically acceptable salts thereof. Compositions containing them, methods for their preparation and their use as pharmaceuticals are also described.Type: GrantFiled: June 14, 2002Date of Patent: August 21, 2007Assignee: Novartis AGInventors: Gurdip Bhalay, Clive Victor Walker
-
Methods for determining the risk of developing asthma characterized by bronchial hyperresponsiveness
Patent number: 7122311Abstract: The invention relates to the use of an asthma-associated gene, designated AAGA, the protein molecule encoded by AAGA and related molecules in diagnostic and prognostic screening of patient populations, to polymorphisms in AAGA, and to the use of the protein encoded by AAGA or a variant thereof as a therapeutic target.Type: GrantFiled: July 12, 2002Date of Patent: October 17, 2006Assignees: Novartis AG, Wake Forest University Health Sciences, Rijksuniversiteit GroningenInventors: Paul Andrew Whittaker, Deborah Alexis Meyers, Dirkje Sjoukje Postma, Eugene Roland Bleecker -
Patent number: 7122184Abstract: The invention concerns momoclonal antibodies to terbinafine in free base or salt form, immunogenic conjugates suitable for preparing them, hybridoma capable of producing them, and corresponding assay kits. The antibodies can be prepared by administering to an appropriate animal an immunogenic conjugate of a suitable derivative of terbinafine covalently linked to an immonogen, recovering antibody-producing cells sensitized to the conjugate, immortalizing the antibody-producing cells, selecting a resultant immortalized cell line, and recovering the resultant antibodies therefrom. They are indicated for use in particular in the measurement of terbinafine tissue concentration and distribution in bodily fluids or compartments, especially nails.Type: GrantFiled: February 12, 2001Date of Patent: October 17, 2006Assignee: Novartis AGInventors: Birgit Dorobek, Peter Nussbaumer
-
Patent number: 7109202Abstract: Compounds of formula (I) in free or salt form, where A is a C6-C15 monovalent aromatic group. R1 is hydrogen, phenyl optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, C1–C8-alkyl, C1–C8-haloalkyl, C1–C8-alkoxy, C1–C8-alkoxy-C1–C8-alkyl or acyloxy, or a 5- or 6-membered monovalent heterocyclic group, R2 is hydrogen, C1-C8-alkyl, acyl or CON(R3)R4, provided that R2 is C1–C8-alkyl, acyl or CON(R3)R4 when R1 is hydrogen, R3 and R4 are each independently hydrogen, or C1–C8-alkyl, together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclic group, and Zl, Z2, Z3 and Z4 are each independently N or CR5, at least one of them being CR5, and R5 is hydrogen, C1–C8-alkyl or C1–C8-alkoxy.Type: GrantFiled: November 19, 2001Date of Patent: September 19, 2006Assignee: Novartis AGInventors: Neil J Press, Roger J Taylor
-
Patent number: 7067502Abstract: A medicament containing, separately or together, (A) formoterol or a pharmaceutically acceptable salt thereof or a solvate of formoterol or a solvate of the salt and (B) mometasone furoate, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.Type: GrantFiled: November 20, 2003Date of Patent: June 27, 2006Assignee: Novartis AGInventors: Ian Francis Hassan, Jeremy Guy Clarke, Henry Luke Danahay
-
Patent number: 7041288Abstract: Antibodies and antibody fragments which are anti-idiotypic to an antibody that interferes with the binding of the C?3 region of IgE to its high affinity receptor (mimobodies), particularly, which are anti-idiotypic to BSW17 (BSW17-mimobodies) are described, as well as their use as pharmaceuticals, especially vaccines, in the treatment of IgE-mediated diseases.Type: GrantFiled: October 10, 2001Date of Patent: May 9, 2006Assignee: Novartis AGInventors: Franz Kricek, Beda Stadler, Monique Vogel
-
Patent number: 7034042Abstract: Compounds of formula (I) in free or salt form, where Ar1 is phenyl substituted by one or more substituents selected from halogen, cyano, nitro, and C1–C8-alkyl optionally substituted by cyano or halogen, Ar2 is phenyl optionally which is unsubstituted or substituted by one or more substituents selected from halogen, cyano, hydroxy, nitro, C1–C8-alkyl, C1–C8-haloalkyl, C1–C8-alkoxy or C1–C8-alkoxycarbonyl, R1 is C1–C8-alkyl substituted by hydroxy, C1–C8-alkoxy, acyloxy, —N(R2)R3, halogen, carboxy, C1–C8-alkoxycarbonyl, phenyl-C1–C8-alkoxycarbonyl, —CON(R4)R5 or by a monovalent cyclic organic group, R2 and R?3 are each independently hydrogen or C1–C8-alkyl, or R2 is hydrogen and R3 is acyl or SO2R6, or R2 and R3 together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclic group, R4 and R5 are each independently hydrogen, C1–C8-alkyl optionally substituted by hydroxy or phenyl, or phenyl optionally substituted by C1–C8-alkyl, halogen, cyano or C1–C8-alkoxy, or R4 and R5 togeType: GrantFiled: October 8, 2001Date of Patent: April 25, 2006Assignee: Novartis AGInventors: Gurdip Bhalay, Trevor J Howe, Darren M Le Grand
-
Patent number: 7019136Abstract: A compound of formula (I): R1 is hydrogen or alkyl optionally substituted by hydroxy, alkoxy, or alkylthio, R2 is hydrogen, alkyl, hydroxyalkyl, alkylcarbonyloxyalkyl, alkoxyalkyl, alkylthioalkyl, alkenyl, cycloalkylalkyl, heterocyclylalkyl, aralkyl in which the aryl ring thereof is optionally fused to a 5-membered heterocyclic group or is optionally substituted by one or more substituents selected from alkoxy, amino, alkylamino, dialkylamino, acylamino, halogen, hydroxy, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino or dialkylaminosulfonylamino, R3 is hydrogen or alkyl optionally substituted by hydroxy, alkoxy, or alkylthio, R4 is hydrogen or alkyl, R5 is a quinolinyl, isoquinolinyl or oxodihydroisoquinolinyl group optionally fused to a 5-membered heterocyclic group and optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, alkyl, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkoxy, alkylthio, alkenyl, alkoxycarbonyl, alkynyl, carboxyl, acyl,Type: GrantFiled: September 9, 2004Date of Patent: March 28, 2006Assignee: Novartis, AGInventors: Gurdip Bhalay, Stephen Paul Collingwood, Robin Alec Fairhurst, Sylvie Felicite Gomez, Reto Naef, David Andrew Sandham
-
Patent number: 7008951Abstract: A medicament comprising, separately or together, (A) a compound of formula (I) in free or pharmaceutically acceptable salt or solvate form and (B) a corticosteroid, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease, the molar ratio of (A) to (B) being from 100:1 to 1:300.Type: GrantFiled: August 4, 2004Date of Patent: March 7, 2006Assignee: Novartis AGInventors: Bernard Cuenoud, Robin Alec Fairhurst, Nicholas Lowther
-
Patent number: D520635Type: GrantFiled: March 15, 2004Date of Patent: May 9, 2006Assignee: Novartis AGInventors: Jean-Daniel Bonny, Stefan Hirsch, Oskar Kalb, Peter Pietzonka
-
Patent number: D527817Type: GrantFiled: November 9, 2004Date of Patent: September 5, 2006Assignee: Novartis AGInventors: Dominik Ziegler, Grant Smetham, Mauro Citerio
-
Patent number: D530814Type: GrantFiled: January 20, 2006Date of Patent: October 24, 2006Assignee: Novartis AGInventors: Jean-Daniel Bonny, Stefan Hirsch, Oskar Kalb, Peter Pietzonka
-
Patent number: 5260280Abstract: Sialic acid binding proteins, sialic acid-binding peptides and sialic acid containing oligo-saccharides are active ingredients of a novel bacterial enterotoxin neutralizer and interfere with the binding of enterotoxins, including cholera toxin, to receptors so as to exert an effect of neutralizing the toxicity, thus being utilized as an effective neutralizer and are safe and available cheaply and abundantly from by-products produced during the processing of cow's milk which renders the enterotoxin neutralizer economically advantageous for commercial use.Type: GrantFiled: July 14, 1992Date of Patent: November 9, 1993Assignee: Snow Brand Milk Products Co., Ltd.Inventors: Hiroko Isoda, Yoshihiro Kawasaki, Morimasa Tanimoto, Shunichi Dosako, Tadashi Idota